Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long term treatment with rio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Marra, Alberto M. (Verfasst von) , Benjamin, Nicola (Verfasst von) , Eichstaedt, Christina (Verfasst von) , Egenlauf, Benjamin (Verfasst von) , Harutyunova, Satenik (Verfasst von) , Fischer, Christine (Verfasst von) , Grünig, Ekkehard (Verfasst von)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 19 December 2018
In: Respiratory research
Year: 2018, Jahrgang: 19
ISSN:1465-993X
DOI:10.1186/s12931-018-0957-y
Online-Zugang:Verlag, Volltext: https://doi.org/10.1186/s12931-018-0957-y
Volltext
Verfasserangaben:Alberto M. Marra, Michael Halank, Nicola Benjamin, Eduardo Bossone, Antonio Cittadini, Christina A. Eichstaedt, Benjamin Egenlauf, Satenik Harutyunova, Christine Fischer, Henning Gall, Hossein Ardeschir Ghofrani, Marius M. Hoeper, Tobias J. Lange, Karen M. Olsson, Hans Klose and Ekkehard Grünig
Beschreibung
Zusammenfassung:Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long term treatment with riociguat.
Beschreibung:Gesehen am 14.10.2019
Beschreibung:Online Resource
ISSN:1465-993X
DOI:10.1186/s12931-018-0957-y